Potentiating new neurological pain drugs from Cannabis

Neurology is a complex area, potentially requiring a combination of surgical and non-surgical intervention. Regardless of the intervention plan, neurology is hindered with a number of co-morbidities that can diminish patient outcomes, one in particular is pain. Pain management requires a number of pharmaceutical agents principally from the opioid class of drugs, potentiating heightened secondary organ toxicity profiles. Further it is accepted that some 33% + of patients undergoing chemotherapy will state that their pain is under-managed. Cannabinoids potentiate new treatments in pain management and posit opioid reduction. Theoretically, the argument appears sound; in real world practice, cannabinoid preparations differ vastly ultimately affecting the efficacy of the final product. This presentation will take a first-hand look at Medlab’s work into developing a standardised and validated “early” drug used in clinical trial and suited for Regulatory (TGA, FDA, EMA) acceptance.

Biography

Sean Hall is the MD and Chief Executive Officer at Medlab Clinical LTD, Sydney, Australia. He founded Medlab in August 2012. He has over 20 years’ experience in nutraceutical sales and development, as well as early drug discovery in Australia, Asia and the US. He has led and inspired his teams to author multiple patents, write peer reviewed articles and deliver lectures at scientific conferences. His passion is leading his researchers into novel areas and strong commercialisation opportunities. He was a founder of FIT-BioCeuticals. For his sale of FIT-BioCeuticals to Blackmores in 2012, he was nominated as a finalist in the inaugural Australian Exit CEO of the Year Award. He is a Medical Doctor with an MBA in Clinical Pharmaceutical Management, the American Federation for Medical Researcher, The World Medical Association, A4M and Special Operations Medical Association.